Publisher
Springer Science and Business Media LLC
Reference18 articles.
1. FDA. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions; 2021. https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death20240216. Accessed 2 Oct 2023.
2. Setyawan J, Azimi N, Strand V, Yarur A, Fridman M. Reporting of thromboembolic events with JAK inhibitors: analysis of the FAERS database 2010–2019. Drug Saf. 2021;44:889–97. https://doi.org/10.1007/s40264-021-01082-y.
3. Dong Z, Ye X, Chen C, Wang R, Liu D, Xu X, et al. Thromboembolic events in Janus kinase inhibitors: a pharmacovigilance study from 2012 to 2021 based on the Food and Drug Administration’s Adverse Event Reporting System. Br J Clin Pharmacol. 2022;88:4180–90. https://doi.org/10.1111/bcp.15361.
4. Mytheen S, Varghese A, Joy J, Shaji A, Tom AA. Investigating the risk of deep vein thrombosis with JAK inhibitors: a disproportionality analysis using FDA Adverse Event Reporting System Database (FAERS). Expert Opin Drug Saf. 2023;22:985–94. https://doi.org/10.1080/14740338.2023.2223955.
5. Ota S, Matsuda A, Ogihara Y, Yamada N, Nakamura M, Mori T, et al. Incidence, characteristics and management of venous thromboembolism in Japan during 2011. Circ J. 2018;82:555–60. https://doi.org/10.1253/circj.CJ-17-0579.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献